- Hemoglobin Variability Associated with Different Erythropoiesis Stimulating Agents in Hemodialysis Patients
-
Park SK, Hwang KS, Park JS, Lee CH, Kang CM, Kim GH
- KMID: 2307154
- Korean J Nephrol.
- 2011 Jan;30(1):41-47.
PURPOSE: This study was undertaken to examine whether differences exist in the hemoglobin variability according to the types of erythropoiesis stimulating agent (ESA) in hemodialysis (HD) patients. METHODS: Clinical data were... -
- CITED
-
- Close
- SHARE
-
- Close
- The Efficacy of Once Weekly Compared with Two or Three Times Weekly Subcutaneous Epoetin Alfa (Espogen(R))
-
Lee YK, Lee HS, Joo MH, Kim SG, Seo JW, Oh JE, Yoon JW, Koo JR, Kim HJ, Noh JW
- KMID: 2254047
- Korean J Nephrol.
- 2007 Mar;26(2):220-226.
PURPOSE: Compared with the practice of administrating subcutaneous erythropoietin injection two or three times a week in end-stage renal failure, a weekly administration reduces the frequency of injection and the... -
- CITED
-
- Close
- SHARE
-
- Close
- Effect of High Dose (10, 000 IU) Epoetin Alfa (Espogen(R)) Therapy in CAPD Patients
-
Yeo HM, Kim DJ, Choi SY, Do YS, Jang EH, Baek HJ, Kim MO, Kim HJ, Kim JA, Huh W, Kim YG, Oh HY
- KMID: 2254255
- Korean J Nephrol.
- 2005 May;24(3):441-447.
BACKGROUND: Recombinant human erythropoietin (rHuEPO) is an established treatment for renal anemia. We aimed to determine that high dose subcutaneous epoetin alfa is as efficient and safe as usual dose... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and safety of high dose epoetin alfa therapy in CAPD patients by cross-over study
-
Do JH, Kim DJ, Choi SY, Do YS, Jang EH, Baek HJ, Kim JI, Yeo HM, Choi SC, Lee JE, Huh WS, Kim YG, Oh HY
- KMID: 2305953
- Korean J Med.
- 2006 Nov;71(5):527-534.
BACKGROUND: Recombinant human erythropoietin (rHuEPO) is an essential and well-established treatment for renal anemia. Rcently, clinicians have moved toward administration of high dose rHuEPO to reduce the inconvenience and time... -
- CITED
-
- Close
- SHARE
-
- Close
- Recombinant Human Erythropoietin using Preoperative Autologous Donation in Lumbar Stenosis Operations
-
Lee JH, Yoon KS, Park JS, Kang SB, Do SH, Kim JY
- KMID: 2209791
- J Korean Soc Spine Surg.
- 1999 Dec;6(3):437-442.
STUDY DESIGN: Prospective randomized clinical trial. OBJECTIVES: To determine the minimal effective pretreatment dosage of recombinant human erythropoietin for preoperative autologous donation in lumbar stenosis surgery. SUMMARY OF LITERATURE REVIEW: Preoperative autologous... -
- CITED
-
- Close
- SHARE
-
- Close
- Comparison of Erythropoietic Effect between Epoetin-alpha and Darbepoetin-alpha in Hemodialysis Patients: A Randomized Crossover Study
-
Lee JY, Byun SW, Yeo YS, Yang WS, Park SK, Park JS, Chang JW
- KMID: 2253165
- Korean J Nephrol.
- 2009 Sep;28(5):450-455.
PURPOSE: We aim to compare the erythropoietic effects of epoetin-alpha (EA, 4000 IU SC thrice a week) with those of darbepoetin-alpha (DA, 60ug IV weekly, conversion rate to EA=200:1). METHODS: Forty... -
- CITED
-
- Close
- SHARE
-
- Close
- Time-averaged Concentration Hemoglobin and Erythropoietin Requirement According to Hemoglobin of Different Session of HD of the Week
-
Jang EH, Kang WH, Choi SY
- KMID: 2253268
- Korean J Nephrol.
- 2008 May;27(3):319-326.
PURPOSE: The time average hemoglobin concentration (Hb-Tac) is more likely to represent hemodialysis (HD) patients' true hemoglobin due to variable hemoglobin concentration. This study was performed to evaluate the effect... -
- CITED
-
- Close
- SHARE
-
- Close
- The Effects of Recombinant Human Erythropoietin Therapy on Exercise Capacity and Quality of Life in Dialyzed Patients with End Stage Renal Diseae
-
Choi EJ, Song HC, Jin DC, Chang YS, Yun SN, Kim SY, Yoon SA, Ahn SJ, Lee SH, Shin YS, Park CH, Kim YW, Yang CW, Kim YS, Bang BK
- KMID: 2307385
- Korean J Nephrol.
- 1997 Sep;16(3):501-508.
To determine whether rHuEPO improves the exercise capacity and the global quality of life, 52 nondiabetic patients with end stage renal disease undergoing dialysis (hemodialysis 42, CAPD 10, M 34,... -
- CITED
-
- Close
- SHARE
-
- Close
